Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TETRACHEL vs AMZEEQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.
Infections caused by susceptible strains of Rickettsiae,Mycoplasma pneumoniae infections,Psittacosis (ornithosis),Chlamydia trachomatis infections (e.g., uncomplicated urethral, endocervical, rectal),Brucellosis (in conjunction with streptomycin),Chancroid,Granuloma inguinale,Lymphogranuloma venereum,Relapsing fever,Bartonellosis,Plague,Tularemia,Acute intestinal amebiasis (adjunctive therapy),Severe acne,Propionibacterium acnes infections,Off-label: Helicobacter pylori eradication (as part of quadruple therapy)
FDA-approved for the treatment of inflammatory lesions of rosacea
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal half-life is approximately 28 days due to accumulation in the skin and hair follicles; clinical context: supports once-weekly dosing.
Tetracycline is primarily metabolized in the liver via glucuronidation and undergoes enterohepatic circulation. Minor metabolism may involve microsomal enzymes.
Minimal systemic absorption; not extensively metabolized.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Renal: 30% as unchanged drug; Fecal: 70% as metabolites and unchanged drug via biliary excretion.
65% (primarily albumin).
99% bound to plasma proteins, primarily albumin and lipoproteins.
1.3 L/kg (extensive tissue penetration, including bone and teeth).
Approximately 12 L/kg, indicating extensive distribution into tissues including skin and sebaceous glands.
Oral: 77-96% (decreased by food, dairy, antacids).
Topical: Minimal systemic absorption, approximately 1% of applied dose.
Cr Cl >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: 250 mg once daily. Cr Cl <30 m L/min: 125 mg once daily.
No dosage adjustment required for renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: 250 mg once daily. Child-Pugh C: 125 mg once daily.
No dosage adjustment required for hepatic impairment.
Children ≥8 years: 5 mg/kg orally once daily (max 500 mg) for 28 days.
Not recommended for patients under 12 years of age; safety and efficacy not established.
Initiate at low end of dosing range; monitor renal function and adjust dose based on Cr Cl.
No specific dose adjustment; use same as adults with caution for skin fragility.
Tetracycline can cause fetal harm when administered to a pregnant woman. Use during tooth development (last half of pregnancy, infancy, and children up to 8 years) may cause permanent discoloration of teeth (yellow-gray-brown). It should not be used in this age group unless other drugs are not likely to be effective or are contraindicated.
No black box warning.
Photosensitivity: exaggerated sunburn reaction; avoid direct sunlight and UV light.,Hepatotoxicity: may cause liver damage, especially in patients with renal impairment or receiving high doses.,Renal impairment: accumulation may occur; dosage adjustment required.,Superinfection: use of tetracycline may result in overgrowth of non-susceptible organisms, including fungi.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea has been reported.,Intracranial hypertension: bulging fontanelles in infants and benign intracranial hypertension in adults.,Tissue irritation: avoid extravasation; thrombophlebitis risk with IV administration.
Use may result in overgrowth of nonsusceptible organisms including fungi.,Avoid contact with eyes, mouth, and mucous membranes.,Not for oral, ophthalmic, or intravaginal use.
Hypersensitivity to tetracyclines or any component of the formulation.,Pregnancy (especially second and third trimesters) and lactation.,Children under 8 years of age (except for specific infections like anthrax or where no alternative exists).,Severe hepatic impairment.
Hypersensitivity to any component of the formulation.
Avoid dairy products, calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum, as they reduce absorption. Iron supplements, bismuth subsalicylate, and zinc also chelate tetracyclines. Take tetracycline 1 hour before or 2 hours after meals. Avoid alcohol (hepatotoxicity risk).
No significant food interactions reported with topical AMZEEQ. However, oral minocycline absorption is affected by dairy products; for topical foam, no dietary restrictions are necessary.
Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third trimesters (weeks 13 to 40) is associated with permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia in the child. Additionally, there is a risk of retarded skeletal growth and potentially reversible inhibition of bone growth. Use during the first trimester is generally discouraged unless no alternative therapy is available, as there may be a small risk of teratogenicity (e.g., neural tube defects, cardiovascular malformations) based on some observational studies, though evidence is conflicting.
Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk from systemic absorption.
Tetracycline is excreted into human milk, with milk-to-plasma ratio (M/P) approximately 0.5-0.8. Low levels of tetracycline are found in breast milk; however, due to potential for serious adverse reactions (e.g., permanent tooth discoloration and bone growth inhibition) in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Alternative antibiotics with better safety profiles in lactation are preferred.
Unknown if excreted in human milk; M/P ratio not available. Use with caution; avoid application to breast area.
Due to physiological changes in pregnancy (increased plasma volume, increased renal clearance), tetracycline may achieve lower serum concentrations. However, specific dosing adjustment guidelines for tetracycline in pregnancy are not established. The drug is generally avoided in pregnancy, particularly after the first trimester. If use is necessary in the first trimester, standard dosing based on non-pregnant adults is typically used, but careful monitoring for efficacy and toxicity is recommended. No dose adjustment is recommended for hepatic or renal impairment in pregnancy as the drug is contraindicated in such conditions.
No dosage adjustment required; pharmacokinetics in pregnancy not studied.
Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis. Avoid in children under 8 years and pregnant/breastfeeding women due to bone and tooth discoloration. Administer on an empty stomach (1 hour before or 2 hours after meals) with a full glass of water to prevent esophagitis. Do not take with dairy, antacids, or iron supplements as they chelate and reduce absorption. Photosensitivity risk: advise sun avoidance and sunscreen use.
AMZEEQ (minocycline) 4% foam is a topical antibiotic indicated for inflammatory lesions of rosacea. Avoid contact with eyes and mucous membranes. Use once daily. May cause skin yellowing (pseudolacte) and hyperpigmentation, especially in dark-skinned patients. Consider sunscreen use due to photosensitivity risk. Not for oral administration.
Take this medication on an empty stomach with a full glass of water.,Avoid dairy products, antacids, and iron supplements within 2 hours of taking this drug.,Use sunscreen and protective clothing to prevent severe sunburn.,Complete the full course of therapy even if you feel better.,Report any signs of allergic reaction, severe headache, or vision changes immediately.
Apply foam to affected areas of face once daily, avoiding eyes and mouth.,Wash hands after application.,May cause temporary yellowing of skin or fingernails; not harmful.,Use sunscreen and protective clothing to prevent sunburn.,Do not swallow or apply to large skin areas.,Inform doctor if pregnant, breastfeeding, or planning pregnancy.,Avoid using other topical products on treated areas unless directed by doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TETRACHEL vs AMZEEQ, answered by our medical review team.
TETRACHEL is a Tetracycline Antibiotic that works by Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. AMZEEQ is a Tetracycline Antibiotic that works by Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TETRACHEL and AMZEEQ depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TETRACHEL is: 500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.. The standard adult dose of AMZEEQ is: Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TETRACHEL and AMZEEQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TETRACHEL is classified as Category C. Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third tri. AMZEEQ is classified as Category C. Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk fr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.